{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:11:39Z","timestamp":1789193499971,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS070715"],"award-info":[{"award-number":["R01NS070715"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA039167"],"award-info":[{"award-number":["R01DA039167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA009045"],"award-info":[{"award-number":["R01DA009045"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007027"],"award-info":[{"award-number":["T32DA007027"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00213-017-4758-7","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T01:11:50Z","timestamp":1508807510000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain\/itch-stimulated and pain\/itch-depressed behaviors in male rats"],"prefix":"10.1007","volume":"235","author":[{"given":"Matthew L.","family":"Lazenka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan J.","family":"Moerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Andrew","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Ivy","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Stevens","family":"Negus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"4758_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1124\/jpet.114.219873","volume":"352","author":"AA Altarifi","year":"2015","unstructured":"Altarifi AA, Rice KC, Negus SS (2015) Effects of mu-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of mu-agonist efficacy and noxious stimulus intensity. J Pharmacol Exp Ther 352:208\u2013217","journal-title":"J Pharmacol Exp Ther"},{"key":"4758_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.drugalcdep.2010.05.003","volume":"111","author":"MJ Baggott","year":"2010","unstructured":"Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J (2010) Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend 111:250\u2013256","journal-title":"Drug Alcohol Depend"},{"key":"4758_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000044967","volume":"78","author":"EV Balaskas","year":"1998","unstructured":"Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A (1998) Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 78:395\u2013402","journal-title":"Nephron"},{"key":"4758_CR4","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2460\/javma.233.8.1278","volume":"233","author":"DC Brown","year":"2008","unstructured":"Brown DC, Boston RC, Coyne JC, Farrar JT (2008) Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc 233:1278\u20131283","journal-title":"J Am Vet Med Assoc"},{"key":"4758_CR5","doi-asserted-by":"publisher","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","volume":"9","author":"TF Brust","year":"2016","unstructured":"Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, Aube J, Jones SR, Martin TJ, Bohn LM (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9:ra117","journal-title":"Sci Signal"},{"key":"4758_CR6","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1038\/nprot.2007.441","volume":"2","author":"WA Carlezon Jr","year":"2007","unstructured":"Carlezon WA Jr, Chartoff EH (2007) Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2:2987\u20132995","journal-title":"Nat Protoc"},{"key":"4758_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1124\/jpet.105.092304","volume":"316","author":"WA Carlezon Jr","year":"2006","unstructured":"Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440\u2013447","journal-title":"J Pharmacol Exp Ther"},{"key":"4758_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejphar.2004.08.028","volume":"501","author":"I Carroll","year":"2004","unstructured":"Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS (2004) Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol 501:111\u2013119","journal-title":"Eur J Pharmacol"},{"key":"4758_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.pain.2012.01.016","volume":"153","author":"EJ Cobos","year":"2012","unstructured":"Cobos EJ, Ghasemlou N, Araldi D, Segal D, Duong K, Woolf CJ (2012) Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexive test for evaluating inflammatory pain and analgesia. Pain 153:876\u2013884","journal-title":"Pain"},{"key":"4758_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-3-662-44605-8_16","volume":"226","author":"A Cowan","year":"2015","unstructured":"Cowan A, Kehner GB, Inan S (2015) Targeting itch with ligands selective for kappa opioid receptors. Handb Exp Pharmacol 226:291\u2013314","journal-title":"Handb Exp Pharmacol"},{"key":"4758_CR12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-3565(25)11117-8","volume":"261","author":"RE Davis","year":"1992","unstructured":"Davis RE, Callahan MJ, Dickerson M, Downs DA (1992) Pharmacologic activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys. J Pharmacol Exp Ther 261:1044\u20131049","journal-title":"J Pharmacol Exp Ther"},{"key":"4758_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejphar.2015.05.054","volume":"761","author":"KM DiMattio","year":"2015","unstructured":"DiMattio KM, Ehlert FJ, Liu-Chen LY (2015) Intrinsic relative activities of kappa opioid agonists in activating Galpha proteins and internalizing receptor: differences between human and mouse receptors. Eur J Pharmacol 761:235\u2013244","journal-title":"Eur J Pharmacol"},{"key":"4758_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejphar.2015.07.018","volume":"763","author":"S Dogra","year":"2015","unstructured":"Dogra S, Yadav PN (2015) Biased agonism at kappa opioid receptors: implication in pain and mood disorders. Eur J Pharmacol 763:184\u2013190","journal-title":"Eur J Pharmacol"},{"key":"4758_CR15","doi-asserted-by":"crossref","unstructured":"Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, Immpact (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113: 9\u201319","DOI":"10.1016\/j.pain.2004.09.012"},{"key":"4758_CR16","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0024-3205(99)00417-8","volume":"65","author":"T Endoh","year":"1999","unstructured":"Endoh T, Matsuura H, Tajima A, Izumimoto N, Tajima C, Suzuki T, Saitoh A, Suzuki T, Narita M, Tseng L, Nagase H (1999) Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. Life Sci 65:1685\u20131694","journal-title":"Life Sci"},{"key":"4758_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0014-2999(99)00815-8","volume":"387","author":"T Endoh","year":"2000","unstructured":"Endoh T, Tajima A, Suzuki T, Kamei J, Narita M, Tseng L, Nagase H (2000) Characterization of the antinociceptive effects of TRK-820 in the rat. Eur J Pharmacol 387:133\u2013140","journal-title":"Eur J Pharmacol"},{"key":"4758_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1254\/jjp.85.282","volume":"85","author":"T Endoh","year":"2001","unstructured":"Endoh T, Tajima A, Izumimoto N, Suzuki T, Saitoh A, Suzuki T, Narita M, Kamei J, Tseng LF, Mizoguchi H, Nagase H (2001) TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys. Jpn J Pharmacol 85:282\u2013290","journal-title":"Jpn J Pharmacol"},{"key":"4758_CR19","unstructured":"European Medicines Agency (2013) Assessment report: Winfuran. European Medicines Agency:Committee for Medicinal Products for Human Use"},{"key":"4758_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0304-3959(98)00237-1","volume":"80","author":"MJ Field","year":"1999","unstructured":"Field MJ, Carnell AJ, Gonzalez MI, McCleary S, Oles RJ, Smith R, Hughes J, Singh L (1999) Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain 80:383\u2013389","journal-title":"Pain"},{"key":"4758_CR21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.115.226803","volume":"355","author":"KC Freitas","year":"2015","unstructured":"Freitas KC, Carroll FI, Negus SS (2015) Effects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats. J Pharmacol Exp Ther 355:341\u2013350","journal-title":"J Pharmacol Exp Ther"},{"key":"4758_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1196\/annals.1316.050","volume":"1025","author":"K Hasebe","year":"2004","unstructured":"Hasebe K, Kawai K, Suzuki T, Kawamura K, Tanaka T, Narita M, Nagase H, Suzuki T (2004) Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann N Y Acad Sci 1025:404\u2013413","journal-title":"Ann N Y Acad Sci"},{"key":"4758_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1476-5381.1990.tb12110.x","volume":"101","author":"JC Hunter","year":"1990","unstructured":"Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC, Hughes J (1990) CI-977, a novel and selective agonist for the kappa-opioid receptor. Br J Pharmacol 101:183\u2013189","journal-title":"Br J Pharmacol"},{"key":"4758_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CCID.S55942","volume":"8","author":"S Inui","year":"2015","unstructured":"Inui S (2015) Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol 8:249\u2013255","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"4758_CR25","doi-asserted-by":"crossref","unstructured":"Jaiswal D, Uzans D, Hayden J, Kiberd BA, Taennankore KK (2016) Targeting the opioid pathway for uremic pruritus: a systematic review and meta-analysis. Can J Kidney Health Dis In press","DOI":"10.1177\/2054358116675345"},{"key":"4758_CR26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1152\/jn.00431.2001","volume":"87","author":"SL Jinks","year":"2002","unstructured":"Jinks SL, Carstens E (2002) Responses of superficial dorsal horn neurons to intradermal serotonin and other irritants: comparison with scratching behavior. J Neurophysiol 87:1280\u20131289","journal-title":"J Neurophysiol"},{"key":"4758_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.drugalcdep.2010.11.005","volume":"115","author":"MW Johnson","year":"2011","unstructured":"Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115:150\u2013155","journal-title":"Drug Alcohol Depend"},{"key":"4758_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-017-0721-6","volume":"18","author":"R Kandasamy","year":"2017","unstructured":"Kandasamy R, Lee AT, Morgan MM (2017) Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats. J Headache Pain 18:5","journal-title":"J Headache Pain"},{"key":"4758_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00213-010-1819-6","volume":"210","author":"B Kivell","year":"2010","unstructured":"Kivell B, Prisinzano TE (2010) Kappa opioids and the modulation of pain. Psychopharmacology 210:109\u2013119","journal-title":"Psychopharmacology"},{"key":"4758_CR30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1152\/jn.00302.2011","volume":"106","author":"A Klein","year":"2011","unstructured":"Klein A, Carstens MI, Carstens E (2011) Facial injections of pruritogens or algogens elicit distinct behavior responses in rats and excite overlapping populations of primary sensory and trigeminal subnucleus caudalis neurons. J Neurophysiol 106:1078\u20131088","journal-title":"J Neurophysiol"},{"key":"4758_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000341268","volume":"36","author":"H Kumagai","year":"2012","unstructured":"Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, Kurihara M, Yanagita T, Suzuki H (2012) Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol 36:175\u2013183","journal-title":"Am J Nephrol"},{"key":"4758_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/jpet.112.197780","volume":"343","author":"AJ Kwilasz","year":"2012","unstructured":"Kwilasz AJ, Negus SS (2012) Dissociable effects of the cannabinoid receptor agonists Delta9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats. J Pharmacol Exp Ther 343:389\u2013400","journal-title":"J Pharmacol Exp Ther"},{"key":"4758_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/npp.2013.236","volume":"39","author":"MD Leitl","year":"2014","unstructured":"Leitl MD, Onvani S, Bowers MS, Cheng K, Rice KC, Carlezon WA Jr, Banks ML, Negus SS (2014) Pain-related depression of the mesolimbic dopamine system in rats: expression, blockade by analgesics, and role of endogenous kappa-opioids. Neuropsychopharmacology 39:614\u2013624","journal-title":"Neuropsychopharmacology"},{"key":"4758_CR34","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S1734-1140(11)70694-6","volume":"63","author":"J Listos","year":"2011","unstructured":"Listos J, Merska A, Fidecka S (2011) Pharmacological activity of salvinorin A, the major component of Salvia divinorum. Pharmacol Rep 63:1305\u20131309","journal-title":"Pharmacol Rep"},{"key":"4758_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00213-012-2912-9","volume":"226","author":"KA MacLean","year":"2013","unstructured":"MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR (2013) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology 226:381\u2013392","journal-title":"Psychopharmacology"},{"key":"4758_CR36","unstructured":"McGrath PJ, Unruh AM (2013) Measurement and assessment of pediatric pain. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC (eds) Wall and Melzack\u2019s textbook of pain, 6th Edition. Elsevier, Philadelphia, pp 320\u2013327"},{"key":"4758_CR37","first-page":"301","volume-title":"Wall and Melzack\u2019s textbook of pain","author":"R Melzack","year":"2013","unstructured":"Melzack R, Katz J (2013) Pain measurement in adult patients. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC (eds) Wall and Melzack\u2019s textbook of pain, 6th edn. Elsevier, Philadelphia, pp 301\u2013319","edition":"6"},{"key":"4758_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1248\/cpb.46.366","volume":"46","author":"H Nagase","year":"1998","unstructured":"Nagase H, Hayakawa J, Kawamura K, Kawai K, Takezawa Y, Matsuura H, Tajima C, Endo T (1998) Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull (Tokyo) 46:366\u2013369","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"4758_CR39","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2011","unstructured":"National Research Council (2011) Guide for the care and use of laboratory animals. National Academies Press, Washington DC"},{"key":"4758_CR40","volume-title":"Guidelines for the care and use of mammals in neuroscience and behavioral research","author":"National_Research_Council","year":"2003","unstructured":"National_Research_Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. The National Academies Press, Washington, DC"},{"key":"4758_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/laban.255","volume":"42","author":"SS Negus","year":"2013","unstructured":"Negus SS (2013) Expression and treatment of pain-related behavioral depression. Lab Anim (NY) 42:292\u2013300","journal-title":"Lab Anim (NY)"},{"key":"4758_CR42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1124\/pr.112.007419","volume":"66","author":"SS Negus","year":"2014","unstructured":"Negus SS, Miller LL (2014) Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev 66:869\u2013917","journal-title":"Pharmacol Rev"},{"key":"4758_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1124\/jpet.106.106377","volume":"319","author":"SS Negus","year":"2006","unstructured":"Negus SS, Vanderah TW, Brandt MR, Bilsky EJ, Becerra L, Borsook D (2006) Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J Pharmacol Exp Ther 319:507\u2013514","journal-title":"J Pharmacol Exp Ther"},{"key":"4758_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00213-009-1770-6","volume":"210","author":"SS Negus","year":"2010","unstructured":"Negus SS, Morrissey EM, Rosenberg M, Cheng K, Rice KC (2010) Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology 210:149\u2013159","journal-title":"Psychopharmacology"},{"key":"4758_CR45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1124\/jpet.111.186783","volume":"340","author":"SS Negus","year":"2012","unstructured":"Negus SS, O'Connell R, Morrissey E, Cheng K, Rice KC (2012a) Effects of peripherally restricted kappa opioid receptor agonists on pain-related stimulation and depression of behavior in rats. J Pharmacol Exp Ther 340:501\u2013509","journal-title":"J Pharmacol Exp Ther"},{"key":"4758_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jpain.2011.12.003","volume":"13","author":"SS Negus","year":"2012","unstructured":"Negus SS, Rosenberg MB, Altarifi AA, O'Connell RH, Folk JE, Rice KC (2012b) Effects of the delta opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats. J Pain 13:317\u2013327","journal-title":"J Pain"},{"key":"4758_CR47","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/j.pain.0000000000000171","volume":"156","author":"SS Negus","year":"2015","unstructured":"Negus SS, Neddenriep B, Altarifi AA, Carroll FI, Leitl MD, Miller LL (2015) Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice. Pain 156:1153\u20131160","journal-title":"Pain"},{"key":"4758_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00002826-199619010-00009","volume":"19","author":"AC Pande","year":"1996","unstructured":"Pande AC, Pyke RE, Greiner M, Cooper SA, Benjamin R, Pierce MW (1996) Analgesic efficacy of the kappa-receptor agonist, enadoline, in dental surgery pain. Clin Neuropharmacol 19:92\u201397","journal-title":"Clin Neuropharmacol"},{"key":"4758_CR49","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pain.2009.04.010","volume":"144","author":"G Pereira Do Carmo","year":"2009","unstructured":"Pereira Do Carmo G, Stevenson GW, Carlezon WA, Negus SS (2009) Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain 144:170\u2013177","journal-title":"Pain"},{"key":"4758_CR51","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jpain.2012.11.006","volume":"14","author":"MB Rosenberg","year":"2013","unstructured":"Rosenberg MB, Carroll FI, Negus SS (2013) Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats. J Pain 14:246\u2013259","journal-title":"J Pain"},{"key":"4758_CR52","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1021\/jm1004978","volume":"53","author":"SP Runyon","year":"2010","unstructured":"Runyon SP, Brieaddy LE, Mascarella SW, Thomas JB, Navarro HA, Howard JL, Pollard GT, Carroll FI (2010) Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity. J Med Chem 53:5290\u20135301","journal-title":"J Med Chem"},{"key":"4758_CR53","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","volume":"32","author":"SS Schattauer","year":"2017","unstructured":"Schattauer SS, Kuhar JR, Song A, Chavkin C (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cell Signal 32:59\u201365","journal-title":"Cell Signal"},{"key":"4758_CR54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0304-3959(94)00194-J","volume":"61","author":"L Seguin","year":"1995","unstructured":"Seguin L, Le Marouille-Girardon S, Millan MJ (1995) Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent. Pain 61:325\u2013343","journal-title":"Pain"},{"key":"4758_CR55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/00015550152572868","volume":"81","author":"JS Thomsen","year":"2001","unstructured":"Thomsen JS, Petersen MB, Benfeldt E, Jensen SB, Serup J (2001) Scratch induction in the rat by intradermal serotonin: a model for pruritus. Acta Derm Venereol 81:250\u2013254","journal-title":"Acta Derm Venereol"},{"key":"4758_CR56","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","volume":"172","author":"MS Todtenkopf","year":"2004","unstructured":"Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr (2004) Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 172:463\u2013470","journal-title":"Psychopharmacology"},{"key":"4758_CR57","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0014-2999(01)01588-6","volume":"435","author":"Y Togashi","year":"2002","unstructured":"Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, Kawamura K, Endoh T, Utsumi J, Kamei J, Tanaka T, Nagase H (2002) Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 435:259\u2013264","journal-title":"Eur J Pharmacol"},{"key":"4758_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1527-3458.2003.tb00248.x","volume":"9","author":"ML Wadenberg","year":"2003","unstructured":"Wadenberg ML (2003) A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist. CNS Drug Rev 9:187\u2013198","journal-title":"CNS Drug Rev"},{"key":"4758_CR59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/jpet.114.216820","volume":"352","author":"KL White","year":"2015","unstructured":"White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, Nichols DE, Malanga CJ, Roth BL (2015) The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther 352:98\u2013109","journal-title":"J Pharmacol Exp Ther"},{"key":"4758_CR60","doi-asserted-by":"publisher","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","volume":"288","author":"L Zhou","year":"2013","unstructured":"Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, Madoux F, Cameron MD, Prisinzano TE, Aube J, Bohn LM (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 288:36703\u201336716","journal-title":"J Biol Chem"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4758-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4758-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4758-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:05:16Z","timestamp":1750961116000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4758-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["4758"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4758-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]},"assertion":[{"value":"9 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}}]}}